Company news
Arcturus Therapeutics Holdings Inc. news in 2020
Arcturus Therapeutics Holdings Inc.'s news releases, calls and decks from 2020, newest first.
Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung Disease
December 29, 2020
Arcturus Therapeutics Received Approval from Singapore Health Sciences Authority to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate and Provides New and Updated Clinical and Preclinical Data
December 27, 2020
Arcturus Therapeutics Announces Proposed Public Offering of Common Stock
December 6, 2020
Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
December 6, 2020
Arcturus Therapeutics Announces Initiation of Dosing ARCT-810 in Patients with Ornithine Transcarbamylase (OTC) Deficiency
December 6, 2020
Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data
November 8, 2020
Arcturus Therapeutics Announces Positive Interim ARCT-021 (LUNAR-COV19) Phase 1/2 Study Results for Both Single Shot and Prime-boost Regimens, and Up to $220 Million in Additional Financial Commitments from Singapore
November 8, 2020
Arcturus Therapeutics to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Nov 9, 2020
October 29, 2020
Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
October 4, 2020
Arcturus Therapeutics to Present at Guggenheim’s Vaccines and Infectious Diseases Conference
September 30, 2020
Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate
September 3, 2020
Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health
August 17, 2020
Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study
August 10, 2020
Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update
August 9, 2020
Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer
August 5, 2020
Arcturus Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020
August 3, 2020
Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 30, 2020
Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock
July 28, 2020
Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19
July 22, 2020
Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19
July 20, 2020
Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board
June 30, 2020
Arcturus Therapeutics to be Added to Russell 2000® Index
June 28, 2020
Arcturus Therapeutics to Present at the Raymond James Human Health Innovation Virtual Conference
June 10, 2020
Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency
June 4, 2020
Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19)
May 7, 2020
Arcturus Therapeutics Announces First Quarter 2020 Financial Results and Provides a Corporate Update
May 6, 2020
Arcturus Therapeutics to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 7, 2020
May 3, 2020
Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine
May 3, 2020
Arcturus Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate
April 26, 2020
Arcturus Therapeutics Announces Pricing of $70.0 Million Public Offering of Common Stock
April 15, 2020
Arcturus Therapeutics Announces Allowance of IND & Approval of Clinical Trial Application (CTA) for ARCT-810, a First-in-Class Investigational mRNA Medicine to Treat Ornithine Transcarbamylase Deficiency
April 12, 2020
Arcturus Therapeutics Announces Clinical Trial Timeline for its COVID-19 Vaccine
April 8, 2020
Arcturus COVID-19 Vaccine to Benefit from Duke-NUS Genetic Correlation System
March 26, 2020
Arcturus Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results
March 10, 2020
Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR Technology™
March 3, 2020
Arcturus Therapeutics to Report Fourth Quarter and Year-End 2019 Financial Results and Provide Corporate Update on March 11
February 23, 2020
Arcturus Therapeutics to Present at Two Investor Conferences in March
February 18, 2020
Arcturus Therapeutics Appoints Steve Hughes, M.D., as Chief Development Officer
January 7, 2020
Calls in 2020
Decks in 2020
- Investor Presentation (December 2020)
Investor deck · 45 slides · Dec 8, 2020
- Investor Presentation (June 2020)
Investor deck · 38 slides · Jun 18, 2020
- Investor Presentation (January 2020)
Investor deck · 25 slides · Jan 10, 2020